108 related articles for article (PubMed ID: 27798863)
21. Cytotoxic activity and cytostatic mechanism of novel 2-arylbenzo[b]furans.
Yang H; Pang JY; Cai YC; Xu ZL; Xian LJ
J Pharm Pharmacol; 2006 Sep; 58(9):1281-7. PubMed ID: 16945188
[TBL] [Abstract][Full Text] [Related]
22. Piperine enhances the efficacy of TRAIL-based therapy for triple-negative breast cancer cells.
Abdelhamed S; Yokoyama S; Refaat A; Ogura K; Yagita H; Awale S; Saiki I
Anticancer Res; 2014 Apr; 34(4):1893-9. PubMed ID: 24692724
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant docetaxel/cyclophosphamide in triple-negative breast cancer: predictive value of class III-β tubulin and non-basal subtype.
Shimada K; Ishikawa T; Kita K; Narui K; Sugae S; Shimizu D; Tanabe M; Sasaki T; Chishima T; Ichikawa Y; Endo I
Anticancer Res; 2015 Feb; 35(2):907-12. PubMed ID: 25667473
[TBL] [Abstract][Full Text] [Related]
24. Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer.
Lin HR; Safo MK; Abraham DJ
Bioorg Med Chem Lett; 2007 May; 17(9):2581-9. PubMed ID: 17337183
[TBL] [Abstract][Full Text] [Related]
25. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
[TBL] [Abstract][Full Text] [Related]
26. Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell.
Hasanpourghadi M; Karthikeyan C; Pandurangan AK; Looi CY; Trivedi P; Kobayashi K; Tanaka K; Wong WF; Mustafa MR
J Exp Clin Cancer Res; 2016 Mar; 35():58. PubMed ID: 27030360
[TBL] [Abstract][Full Text] [Related]
27. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
28. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
29. The in vivo performance of ferrocenyl tamoxifen lipid nanocapsules in xenografted triple negative breast cancer.
Lainé AL; Adriaenssens E; Vessières A; Jaouen G; Corbet C; Desruelles E; Pigeon P; Toillon RA; Passirani C
Biomaterials; 2013 Sep; 34(28):6949-56. PubMed ID: 23777919
[TBL] [Abstract][Full Text] [Related]
30. The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer.
Makvandi M; Tilahun ED; Lieberman BP; Anderson RC; Zeng C; Xu K; Hou C; McDonald ES; Pryma DA; Mach RH
Biochem Biophys Res Commun; 2015 Nov; 467(4):1070-5. PubMed ID: 26453012
[TBL] [Abstract][Full Text] [Related]
31. Structure-Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells.
Robles AJ; McCowen S; Cai S; Glassman M; Ruiz F; Cichewicz RH; McHardy SF; Mooberry SL
J Med Chem; 2017 Nov; 60(22):9275-9289. PubMed ID: 29053266
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells.
Ravi M; Tentu S; Baskar G; Rohan Prasad S; Raghavan S; Jayaprakash P; Jeyakanthan J; Rayala SK; Venkatraman G
BMC Cancer; 2015 Oct; 15():768. PubMed ID: 26499490
[TBL] [Abstract][Full Text] [Related]
33. Triple negative breast cancer.
Cetin I; Topcul M
Asian Pac J Cancer Prev; 2014; 15(6):2427-31. PubMed ID: 24761842
[TBL] [Abstract][Full Text] [Related]
34. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
35. Aqueous extract of Triphala inhibits cancer cell proliferation through perturbation of microtubule assembly dynamics.
Cheriyamundath S; Mahaddalkar T; Save SN; Choudhary S; Hosur RV; Lopus M
Biomed Pharmacother; 2018 Feb; 98():76-81. PubMed ID: 29245069
[TBL] [Abstract][Full Text] [Related]
36. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM
Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646
[TBL] [Abstract][Full Text] [Related]
37. A novel anti-microtubule agent with carbazole and benzohydrazide structures suppresses tumor cell growth in vivo.
Ohira M; Iwasaki Y; Tanaka C; Kuroki M; Matsuo N; Kitamura T; Yukuhiro M; Morimoto H; Pang N; Liu B; Kiyono T; Amemiya M; Tanaka K; Yoshida K; Sugimoto N; Ohshima T; Fujita M
Biochim Biophys Acta; 2015 Sep; 1850(9):1676-84. PubMed ID: 25960391
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863.
de Ines C; Leynadier D; Barasoain I; Peyrot V; Garcia P; Briand C; Rener GA; Temple C
Cancer Res; 1994 Jan; 54(1):75-84. PubMed ID: 8261466
[TBL] [Abstract][Full Text] [Related]
40. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
